Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Provectus Biopharmaceuticals Inc (OP: PVCT ) 0.1101 -0.0009 (-0.81%) Streaming Delayed Price Updated: 3:59 PM EST, Nov 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 837,440 Open 0.1123 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.1110 Today's Range 0.1090 - 0.1143 52wk Range 0.0445 - 0.2245 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News PVCT Stock Earnings: Provectus Reported Results for Q2 2024 August 13, 2024 Provectus just reported results for the second quarter of 2024. Via InvestorPlace PVCT Stock Earnings: Provectus Reported Results for Q1 2024 May 14, 2024 Provectus just reported results for the first quarter of 2024. Via InvestorPlace Performance YTD +5.06% +5.06% 1 Month +2.61% +2.61% 3 Month +10.65% +10.65% 6 Month -42.05% -42.05% 1 Year -26.16% -26.16% More News Read More PVCT Stock Earnings: Provectus Reported Results for Q4 2023 March 28, 2024 Via InvestorPlace Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December January 17, 2023 Via Benzinga Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023 December 12, 2022 From Provectus Biopharmaceuticals Inc. Via GlobeNewswire Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022 December 01, 2022 From Provectus Biopharmaceuticals Inc. Via GlobeNewswire Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022 November 10, 2022 From Provectus Biopharmaceuticals Inc. Via GlobeNewswire Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient November 02, 2022 From Provectus Biopharmaceuticals Inc. Via GlobeNewswire Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation October 25, 2022 From Provectus Biopharmaceuticals Inc. Via GlobeNewswire Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing September 29, 2022 From Provectus Biopharmaceuticals Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
